Synergistic Therapeutic Strategy of Dual Drug-loaded Lipid Polymer Hybrid Nanoparticles for Breast Cancer Treatment

Abstract

Tran et al.: Dual Drug-loaded Lipid Polymer Hybrid Nanoparticles In this investigation, a smart nanocarrier-loaded docetaxel, a microtubules disrupting agent and vorinostat, a histone deacetylase inhibitor was developed to achieve a synergistic anticancer effect. Dual drug-loaded lipid polymer hybrid nanoparticles were prepared, with easy fabrication and favourable properties including small size, narrow distribution and a high loading effi cacy. The in vitro drug release conducted in phosphatebuffered saline, pH 7.4 and acetate-buffered saline, pH 5.5 media demonstrated the sustained, pH-dependent release profi le. The nanoparticles were effectively taken up by cells, which ensured greater suppression of cell growth. The co-delivery of both drugs exhibited a synergistic effect on the induction of cancer cell apoptosis, resulting in greater inhibition of SCC-7, MCF-7, and MDA-MB-231 cancer cells by the drug-loaded carrier. These promising results may lead to clinical applications with enhanced docetaxel activity.

Utilization of Polymer-Lipid Hybrid Nanoparticles for Targeted Anti-Cancer Therapy

“…The procedures generally include the use of internal or external stimuli. Recently, Tran et al reported the delivery of both docetaxel (DTX) and vorinostat (VRS) via a hybrid vehicle using an amphiphilic block copolymer that self-assembled into the NP with a hydrophobic PLA-poly ( l -aspartic acid) core and further with a hydrophilic PEG-shell layer to form a CSPHNP [ 57 ]. Owing to the pH-sensitive properties of PLA, the hybrid system showed a pH-sensitive, controlled drug release because of the protonation of the carboxylic group in the tumor microenvironment.…”

“…Owing to the pH-sensitive properties of PLA, the hybrid system showed a pH-sensitive, controlled drug release because of the protonation of the carboxylic group in the tumor microenvironment. However, the results showed a higher release rate of VRS than DOX under equivalent acidic conditions [ 57 ]. However, the release rates of drugs were 42% and 25% less, respectively, compared with those observed in the study of Huang et al, who prepared a glutathione (GSH) sensitive prodrug carrier and showed an 85% drug release from the hybrid system when used against ovarian cancer [ 58 ].…”